Evidence map›Paper›PMID 41221490›Full record

ArticleTherapeutic advances in medical oncology2025

PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance.

Sara Pilotto, Lorenzo Belluomini, Federico Monaca, Michele Simbolo, Antonio Agostini, Andrea Mafficini, Stela Golovco, Isabella Sperduti, Emanuele Vita, Alessio Stefani and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sara PilottoSection of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Lorenzo BelluominiSection of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.ORCID https://orcid.org/0000-0003-1981-5499
Federico MonacaComprehensive Cancer Center, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
Michele SimboloDepartment of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
Antonio AgostiniComprehensive Cancer Center, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
Andrea MafficiniDepartment of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
Stela GolovcoDepartment of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
Isabella SperdutiBiostatistics, IRCCS Regina Elena National Cancer Institute, Rome, Lazio, Italy.
Emanuele VitaComprehensive Cancer Center, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.ORCID https://orcid.org/0000-0003-4546-547X
Alessio StefaniUniversità Cattolica del Sacro Cuore, Rome, Italy.
Carmine CarboneComprehensive Cancer Center, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
Geny PiroComprehensive Cancer Center, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
Miriam Grazia FerraraUniversità Cattolica del Sacro Cuore, Rome, Italy.
Filippo LococoComprehensive Cancer Center, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
Vienna LudoviniDivision of Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
Rita ChiariUOC Oncologia, AST Pesaro Urbino, Pesaro, Italy.
Silvia NovelloThoracic Oncology Unit, San Luigi Hospital, University of Turin, Orbassano, Italy.
Vincenzo CorboDepartment of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
Michele MilellaSection of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Aldo ScarpaDepartment of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
Giampaolo TortoraComprehensive Cancer Center, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
Emilio BriaComprehensive Cancer Center, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Largo Francesco Vito, 1, Rome 00168, Italy.ORCID https://orcid.org/0000-0002-2333-704X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although considerable discoveries have been made in the genomic landscape of lung adenocarcinoma, to date, little is known regarding potential prognostic factors and altered pathways in resected squamous non-small-cell lung cancer (squamous-NSCLC). Objective: We aimed to analyze the genomic background of prognostic outlier patients, selected based on a previously validated model, to assess differential genomics, and to investigate its relationship with prognosis. Design: We conducted a retrospective study on three squamous-NSCLC cohorts, integrating next-generation sequencing (NGS)-based genomic profiling and NanoString expression analysis to identify molecular alterations associated with patient prognosis. Methods: NGS analysis of somatic mutations (SM) and copy number variations (CNV) was performed by applying a 409-gene Comprehensive Cancer panel in the training set (Cohort #1) and a 56-gene customized panel in the validation set (Cohort #2). Genomic expression (NanoString) was further evaluated on an additional cohort (Cohort #3). Results: Sixty and thirty-seven ( Conclusion: This integrated multi-step analysis identified potentially altered pathways with a biological impact on squamous-NSCLC oncogenesis, suggesting that the PI3KCA/mTOR pathway could affect the prognosis of resected SCC patients through both genomic aberrations and impaired expression.

Indexed as

lung cancermTORC2next-generation sequencingRICTORsquamous

Identifiers

PMID41221490
PMCPMC12597913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.